Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Gross Profit (2016 - 2025)

Iradimed (IRMD) has disclosed Gross Profit for 13 consecutive years, with $16.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit rose 16.22% to $16.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $62.1 million, a 12.82% increase, with the full-year FY2024 number at $56.3 million, up 12.34% from a year prior.
  • Gross Profit was $16.5 million for Q3 2025 at Iradimed, up from $16.0 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $16.5 million in Q3 2025 to a low of $7.1 million in Q1 2021.
  • A 5-year average of $12.0 million and a median of $12.2 million in 2023 define the central range for Gross Profit.
  • Biggest YoY gain for Gross Profit was 48.73% in 2021; the steepest drop was 9.26% in 2021.
  • Iradimed's Gross Profit stood at $9.2 million in 2021, then grew by 21.3% to $11.2 million in 2022, then rose by 19.54% to $13.4 million in 2023, then increased by 10.05% to $14.8 million in 2024, then increased by 11.74% to $16.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Gross Profit are $16.5 million (Q3 2025), $16.0 million (Q2 2025), and $14.8 million (Q1 2025).